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Abstract 
Survivin is an inhibitor of apoptosis whose expression may be associated with inferior 
outcome in patients with diffuse large B-cell lymphoma (DLBCL) treated without rituximab. 
Caspase-3 is the final caspase of the apoptotic cascade and its pattern of expression may also 
be related to patients’ outcome. In this study we investigated immunohistochemical 
expression of survivin and caspase-3 (CPP32) in 57 patients with DLBCL treated with 
rituximab and CHOP (R-CHOP).  According to previously published criteria, we separately 
analyzed correlation of different types of survivin expression with patients’ outcome. Nuclear 
survivin was expressed in only 26% of cases, cytoplasmic survivin was expressed in 81% of 
cases while application of immunoreactivity scoring system yielded 58% of survivin positive 
cases. Caspase-3 was expressed in 77% of cases. There were no significant correlations 
between any type of survivin expression and response to treatment or survival of the patients. 
The expression of caspase-3 was also not associated with patients’ outcome. We conclude that 
survivin and caspase-3 have no significant prognostic significance in patients with DLBCL 
treated with R-CHOP.  
 
Keywords non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, survivin, caspase-3, 
prognostic factors, rituximab, immunohistochemistry  
 
Abbreviations NHL – non-Hodgkin’s lymphoma; DLBCL – diffuse large B-cell lymphoma; 
PS – performance status; ECOG – Eastern Oncology Cooperative Group; IPI – International 
prognostic index, LDH – lactate dehydrogenase; R-CHOP – rituximab, cyclophosphamide, 
doxorubicine, vincristin, prednisone; IAP – inhibitor of apoptosis, IRS –immunoreactivity 
scoring system, (u)CR – (unconfirmed) complete remission.  
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Introduction 
 
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's 
lymphoma (NHL) comprising 30-40% of all cases. Recently, rituximab in combination with 
CHOP (R-CHOP) was established as a new standard of care in patients with DLBCL [1,2]. 
Rituximab is an anti-CD20 monoclonal antibody with various mechanisms of action: antibody 
dependent cellular cytotoxicity (ADCC), complement dependent cytotoxicity (CDC), direct 
induction of apoptosis and increased chemosensitisation i.e. increased sensitivity to 
chemotherapy induced apoptosis [3]. Due to relevance of apoptosis for rituximab antitumor 
activity, the prognostic significance of immunohistochemical expression of survivin and 
caspase-3 was investigated in the present study. For this reason, the expression of bcl-2 was 
also evaluated. 
Survivin belongs to inhibitors of apoptosis proteins (IAP) family. Although IAPs were 
originally described as caspase inhibitors, more recent studies identified survivin as a 
regulator of mitosis, a broad cytoprotective factor, and an effector of cellular adaptation to 
stress [4].  Survivin expression was detected in various tumors and mostly correlated with 
inferior outcome [5]. Immunohistochemical expression of survivin was also investigated in 
DLBCL [6-13]. However, the criteria of immunohistochemical staining positivity were rather 
inconsistent. The majority of studies evaluated nuclear positivity [6-9], two studies evaluated 
cytoplasmic positivity of survivin [10,11], a single study evaluated only intensity of staining 
[12] while in one study the positivity criteria  were not specified [13]. Cut-off values were 
30% percent [6,13], 10% percent [11] or IRS (immunoreactivity scoring system) was applied 
[7-9,12].  Eventually, survivin expression was associated with adverse outcome in four studies 
[6,9,10,12], while other four studies failed to demonstrate this relationship [7,8,11,13].  
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In contrast to survivin, few studies investigated the role of caspase-3 expression in 
lymphoma. Caspase-3 is the final caspase of the apoptotic cascade which activates cytolytic 
enzymes responsible for apoptosis. It was initially discovered that lymphoid tumors show 
stronger expression of caspase-3 than lymphoid hyperplasia [14]. Subsequently, Donoghue et 
al. demonstrated that immunohistochemical localization of caspase-3 can be correlated with 
clinical outcome in DLBCL [15].  More recent studies evaluated expression of active 
(cleaved) caspase-3 [16,17]. However, the expression of active caspase-3 is generally very 
low and it may be difficult to determine if active caspase-3 positive cells are indeed 
neoplastic.  
Although prognostic significance of survivin and caspase-3 have been investigated in 
several studies, none of these studies included patients who were treated with rituximab 
containing regimens. We therefore investigated the expression of survivin and caspase-3 in 
our patients who were treated with R-CHOP.  
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Materials and Methods 
 
This study included 57 consecutive patients with newly diagnosed DLBCL treated with R-
CHOP in our institutions between 2003 and 2007.  Inclusion criteria were available diagnostic 
paraffin block and planned treatment with 4-8 cycles of R-CHOP. Patients with HIV-
associated lymphoma, primary central nervous system lymphoma or transformed lymphoma 
were excluded. Response to treatment was assessed according to standard criteria [18]. 
Complete remission (CR) and unconfirmed complete remission (uCR) after treatment with 4-
8 cycles of R-CHOP +/- radiotherapy were considered as favorable response. Patients 
achieving partial remission, refractory or relapsed patients were treated with second line 
chemotherapy regimens including peripheral blood stem cell transplantation. Clinical 
parameters such as Ann-Arbor stage, performance status (PS) according to Eastern 
Cooperative Oncology Group (ECOG), extranodal involvement, age over or less than 60 and 
lactate dehydrogenase level (LDH) were recorded for each patient to calculate the 
International Prognostic Index (IPI) [19].  
Standard sections for routine hematoxylin and eosin staining were obtained from each 
specimen to confirm the presence of lymphoma.  All diagnostic biopsy specimens were 
reviewed by two hematopathologists. Immunohistochemical stains for CD20 (clone L26; 
dilution 1:200; DAKO, Glostrup, Denmark), CD3 (clone PC3/188A; dilution 1:50; DAKO, 
Glostrup, Denmark), survivin (lot DYX06, dilution 1:300, R&D Systems, Minneapolis, USA) 
caspase-3 (CPP32; clone JHM62, dilution 1:25, Abcam, Cambridge, UK) and bcl-2 (clone 
3.1, dilution 1:50, Novocastra, Newcastle, UK) were performed using the streptavidin-biotin 
complex method. Nuclear and cytoplasmic expression of survivin was evaluated separately 
and the result was considered positive if ≥ 30% tumor cells were stained. The same cut-off 
value was used for bcl-2. In addition, survivin expression was assessed by IRS [8]. Intensity 
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of staining was designated as negative (0), weak (1), moderate (2) or strong (3). The 
percentage of survivin positive cells was scored as either no cells (0), less then 10% of cells 
(1), 10 – 50% of cells (2), 51 – 80% of cells (3) or over 80% of cells stained (4). By 
multiplication of these two parameters, IRS was calculated for each case. Cases were grouped 
as antigen negative (IRS 0 – 6) or antigen positive (IRS 7 – 12). Immunostaining for caspase-
3 was considered positive if ≥ 50% tumor cells were stained [15].  
The analyzed outcomes were response to treatment and overall survival (OS). 
Pretreatment features and response were compared using the χ2 test. OS curves were 
calculated according to the Kaplan-Meier method and the log-rank test was used for 
comparison between groups. Data were analyzed by Statistica software, version 8.0 (StatSoft. 
Inc., Tulsa, OK). A P value <0.05 was considered statistically significant. 
The study was approved by the Ethics committees of the University Hospital Center 
Zagreb and School of Medicine, University of Zagreb. 
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Results 
 
Patients' demographic and clinical characteristics with their response to treatment and survival 
are shown in Table 1.  Out of 57 patients, 46 (81%) achieved complete or unconfirmed 
complete remission and 3-year OS was 66%. After a median follow up of 39 months, 10 
patients who achieved complete remission relapsed and 19 patients died. 
Nuclear survivin was positive in only 15 (26%) of patients (Fig. 1). In contrast, 46 
(81%) showed cytoplasmic expression of survivin (Fig. 2). Both nuclear and cytoplasmic 
positivity was detected in 11 (19%) patients. When survivin was evaluated according to IRS, 
33 (58%) cases were scored as positive (IRS 7-12). Caspase-3 was detected in all cases while 
44 (77%) showed caspase-3 expression in more than 50% of tumor cells. Caspase-3 staining 
was diffuse cytoplasmic, with significant background from non-neoplastic cells (Fig. 3). We 
were not able to differentiate previously described punctuate and cytosolic patterns of 
caspase-3 staining [15]. Bcl-2 was positive in 45 (79%) samples.  
Cytoplasmic expression of survivin correlated with bcl-2 expression (P=0.042). There 
were no significant correlations between any type of survivin expression, caspase-3 and bcl-2 
expression with response to treatment (Table 2). Consecutively, there was no difference in OS 
according to the examined immunohistochemical parameters. However, patients with 
cytoplasmic expression of survivin had a trend toward inferior survival (P=0.072).  
When patients were stratified in two prognostic groups according to IPI, there were 31 
(54%) patients in the favorable (IPI 0-2) and 26 (46%) in the unfavorable group (IPI 3-5).   
In contrast to the immunohistochemical parameters, IPI was a strong predictor of response 
(94% for IPI 0-2 vs. 65% IPI 3-5; P=0.009) and survival (3y-OS was 83% for IPI 0-2 vs. 46% 
for IPI 3-5; P=0.001). 
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Discussion 
 
Our results show that survivin and caspase-3 expression are not of prognostic significance in 
DLBCL treated with R-CHOP. Previously published studies on survivin in DLBCL had 
inconsistent results that supported or negated its adverse prognostic significance [6-13]. In our 
opinion, the principal reason for this discrepancy were inconsistent criteria of survivin 
positivity between studies. Therefore, we used three previously described criteria to evaluate 
results of immunohistochemical staining. We were unable to demonstrate a relation between 
survivin expression and outcome of patients by using any of these criteria. Nonetheless, 
cytoplasmic expression of survivin in comparison with nuclear expression showed a trend 
toward inferior response and survival, although not statistically significant. These results may 
in part correspond to the pivotal study of survivin in DLBCL by Adida et co-workers, who 
demonstrated an adverse role of cytoplasmic survivin on 222 patients [10]. Other reasons that 
may influence results are different clones of antisurvivin antibody used and differences in 
tumor tissue processing [5]. In contrast to all previous studies of survivin in DLBCL, our 
patients were treated with rituximab and CHOP. It is possible that rituximab can neutralize the 
proapoptotic role of survivin and, consequently, its adverse prognostic effect. Likewise, the 
addition of rituximab to CHOP overcomes the bcl-2 associated resistance to chemotherapy 
[20].  In vitro data to support a significant interaction between rituximab and survivin are very 
limited. Only a single experimental study showed that adding rituximab to an antisurvivin 
agent resulted in synergistic antitumor activity in vitro but not in vivo. [21] Recently, an 
inhibitor of survivin expression was tested in a phase I study and showed promising acitivity 
in patients with refractory lymphoma [22]. If antisurvivin agents are indeed effective in 
DLBCL, our data suggest that cytoplasmic expression of survivin should be used for 
treatment optimization. 
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Lack of prognostic significance of caspase-3 expression in our study could also be 
explained by the effect of rituximab. Nevertheless, more likely explanation is that caspase-3 
cannot be evaluated properly because all tumor cells, as well as non-tumor cells, express this 
form of caspase-3. To avoid this problem, more recent studies tested the expression of the 
active form of caspase-3 [16,17].  However, it was demonstrated that prognostic value of 
active caspase-3 is closely related to expression levels of other apoptosis-related proteins. 
Besides, due to very small number of active caspase-3 positive cells, this marker requires a 
double-staining procedure that is inappropriate for routine diagnostic purposes. 
Unlike immunohistochemical parameters, survival of our patients was significantly 
different when they were grouped according to IPI, the only universally accepted prognostic 
factor in DLBCL [19]. Because of limited number of patients in this study, this observation is 
also important for validation of our patients’ cohort.  
Our results show that survivin and caspase-3 cannot predict outcome of patients with 
DLBCL treated with R-CHOP. Different criteria for survivin positivity were used but none 
yielded prognostic significance. We conclude that survivin and caspase-3 are not useful 
prognostic markers in DLBCL.  
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Figure legends:  
Fig. 1 Strong nuclear staining for survivin. Original magnification x400.  
Fig. 2 Cytoplasmic staining for survivin. Original magnification x400. 
Fig. 3 Tumor cells show cytoplasmic expression of caspase-3. Original magnification x400. 
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Table 1 Patients’ characteristics and  
response to the treatment  
 
 
 
 
 
 
 
 
 
 
PS performance status,  
ECOG Eastern Oncology Cooperative Group,  
LDH lactate dehydrogenase,  
(u)CR (unconfirmed) complete remission 
 
 
Characteristic 
No. of patients (%) 
(N = 57) 
 
Median age, range 
(years) 
49 (17-75) 
Male gender 33 (58) 
Stage III or IV 32 (56) 
Age ≥ 60 years 16 (28) 
PS (ECOG) > 1 25 (44) 
Elevated LDH 37 (65) 
> 1 extranodal site 16 (28) 
Response (CR+uCR) 46 (81) 
3-year OS (%) 66% 
 16
Table 2 Patients’ outcomes according to immunohistochemical parameters and IPI  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IRS immunoreactivity scoring system, IPI International prognostic index 
 
Characteristic 
   No. of 
patients (%) 
  Complete  
response (%) 
 
  P 
3-year 
OS 
 
P 
 
Nuclear surviving      
       positive 15 (26) 11 (73) 0.31 65% 0.90 
       negative 42 (74) 35 (83)  66%  
Cytoplasmic survivin             
       positive 46 (81) 35 (76) 0.072 60% 0.072 
       negative 11 (19) 11 (100)  91%  
Survivin according to IRS       
        0 – 6 24 (42) 22 (92) 0.071 59% 0.19 
        7 – 12 33 (58) 24 (73)  75%  
Caspase-3 expression      
       positive  13 (23) 12 (92) 0.21 85% 0.13 
       negative 44 (77) 34 (77)  60%  
 Bcl-2 expression      
       positive 45 (79) 10 (22) 0.99 64% 0.48 
       negative 12 (21) 2 (17)  75%  
  IPI      
        0 – 2 31 (54) 29 (94) 0.009 83% 0.001 
        3 – 5 26 (46) 17 (65)  45%  
